Strong Vyvanse Sales Boost Shire’s First Quarter

Shire posted another strong set of results yesterday, with a 20 percent rise in first-quarter earnings, just beating market expectations, and their attention-deficit hyperactivity disorder (ADHD) treatments and rare disease drugs once again performing well. Shire, whose development has outstripped the industry thanks to its acquisitive strategy, reported earnings per ADS (American Depositary Share) of

Continue Reading

GlaxoSmithKline Announce Q1 Results

Pharmaceutical drug maker, GlaxoSmithKline (GSK), today announced that their revenue increased just 1% in the first quarter, reflecting burdens on the organisation from government price cuts in Europe and some emerging markets, and hard year-by-year comparisons. GSK’s results were boosted by the sale of U.S. rights to a bladder drug, which added approximately £170 million

Continue Reading

Johnson & Johnson Profits Increase

Johnson & Johnson (J&J) yesterday reported a 12.5% growth in earnings for their first quarter, assisted by sales of new products, the most noticeable being the prostate cancer drug Zytiga. The group’s net earnings came in at $3.91 billion, while turnover fell 0.2% to $16.14 billion.  Worldwide pharmaceutical sales were up 1.2% to $6.13 billion,

Continue Reading

Only Medics’ Mobile Website Is Now Live

To further enhance our services we today have launched our new mobile website, offering candidates an easier alternative when searching for their next pharmaceutical physician vacancy using their mobile. With an increasing number of people accessing the internet via their mobiles, Only Medics, as the market-leader and the medical recruitment company of choice for many

Continue Reading

Study Shows Huntington’s Reduces Cancer Risk

According to a study in Sweden, people who have developed Huntington’s disease, a debilitating brain condition, appear have a “protection” from cancer. The findings, which were published in The Lancet Oncology, analysed almost 40 years of medical records, showing that patients with Huntington’s have half the normal expected risk of developing tumours.  However researchers commented

Continue Reading

Eisai Joins Up With Valeant To Promote Halaven

After failing to gain approval from UK cost watchdog, NICE, for the use of Halaven in treating breast cancer, Eisai has linked up with Valeant Pharmaceuticals International, to promote the drug in Central and Eastern Europe. Halaven received European Commission approval in March 2011. Valeant’s PharmaSwiss division will distribute Halaven (eribulin) in Bulgaria, Romania, Latvia,

Continue Reading